patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_748956 | REC_0011901 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 5.9 | 66 | female | 1 | 22 | 4 | 5 | pembrolizumab 200 mg q3w | 12.7 | true | MSS | 2026-03-15T05:35:59.840949+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824699 | REC_0011902 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 17 | 5.7 | 67 | female | 1 | 10 | 5.8 | 2 | osimertinib 80 mg daily | 11.9 | false | MSS | 2026-03-15T05:35:59.841176+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_382617 | REC_0011903 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 14.6 | 64 | female | 0 | 23 | 6.7 | 6 | osimertinib 80 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:59.841414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_561618 | REC_0011904 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 20 | 17.6 | 68 | female | 1 | 7 | 4.9 | 0 | osimertinib 80 mg daily | 29.3 | false | MSI-H | 2026-03-15T05:35:59.841654+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121046 | REC_0011905 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 15 | 58 | female | 0 | 14 | 6.2 | 4 | entrectinib 600 mg daily | 14.3 | true | MSS | 2026-03-15T05:35:59.841895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_714845 | REC_0011906 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 15.2 | 58 | female | 0 | 18 | 6 | 1 | sotorasib 960 mg daily | 15.3 | false | MSI-H | 2026-03-15T05:35:59.842129+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_632280 | REC_0011907 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 19 | 16.8 | 67 | female | 1 | 23 | 4.5 | 1 | pembrolizumab 200 mg q3w | 13.7 | false | MSI-H | 2026-03-15T05:35:59.842366+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_892128 | REC_0011908 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 22 | 5.2 | 70 | male | 1 | 51 | 6.3 | 1 | pembrolizumab 200 mg q3w | 29.7 | false | MSS | 2026-03-15T05:35:59.842598+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692902 | REC_0011909 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 8.9 | 65 | female | 1 | 16 | 6.5 | 5 | alectinib 600 mg BID | 13.7 | false | MSS | 2026-03-15T05:35:59.842881+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_950003 | REC_0011910 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 12.9 | 64 | female | 0 | 24 | 5.5 | 1 | osimertinib 80 mg daily | 13.1 | true | MSI-H | 2026-03-15T05:35:59.843119+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_426174 | REC_0011911 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 14 | 9.4 | 60 | male | 0 | 10 | 4.8 | 6 | osimertinib 80 mg daily | 9.3 | true | MSS | 2026-03-15T05:35:59.843355+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_914924 | REC_0011912 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 12 | 68 | female | 1 | 18 | 7.1 | 2 | osimertinib 80 mg daily | 17.8 | false | MSI-H | 2026-03-15T05:35:59.843599+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_742999 | REC_0011913 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 3.8 | 81 | male | 0 | 11 | 5.4 | 6 | entrectinib 600 mg daily | 9.8 | false | MSS | 2026-03-15T05:35:59.843833+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697061 | REC_0011914 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 9 | 64 | male | 0 | 6 | 4.3 | 6 | osimertinib 80 mg daily | 18 | false | MSS | 2026-03-15T05:35:59.844108+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_731505 | REC_0011915 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 11 | 83 | female | 0 | 19 | 5.7 | 1 | alectinib 600 mg BID | 17.8 | true | MSI-H | 2026-03-15T05:35:59.844348+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_872367 | REC_0011916 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 13.4 | 65 | male | 0 | 5 | 3 | 1 | entrectinib 600 mg daily | 26.9 | true | MSS | 2026-03-15T05:35:59.844585+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_253462 | REC_0011917 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 10.9 | 81 | female | 2 | 15 | 6.7 | 6 | alectinib 600 mg BID | 19.5 | false | MSS | 2026-03-15T05:35:59.844818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_706036 | REC_0011918 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 9.9 | 67 | female | 0 | 13 | 4.3 | 6 | sotorasib 960 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:59.845060+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_559303 | REC_0011919 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 2.8 | 70 | male | 2 | 12 | 7 | 2 | osimertinib 80 mg daily | 11.7 | false | MSS | 2026-03-15T05:35:59.845305+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_906495 | REC_0011920 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 8.6 | 60 | male | 0 | 12 | 5.2 | 2 | sotorasib 960 mg daily | 13.4 | false | MSS | 2026-03-15T05:35:59.845537+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317438 | REC_0011921 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 7.7 | 67 | male | 0 | 15 | 4.7 | 2 | osimertinib 80 mg daily | 12.4 | false | MSS | 2026-03-15T05:35:59.845770+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_386678 | REC_0011922 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 17.4 | 66 | female | 0 | 22 | 5.7 | 2 | osimertinib 80 mg daily | 10.7 | false | MSI-H | 2026-03-15T05:35:59.846060+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_803629 | REC_0011923 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 13.3 | 71 | female | 3 | 6 | 7.3 | 7 | entrectinib 600 mg daily | 11.9 | true | MSS | 2026-03-15T05:35:59.846300+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_780967 | REC_0011924 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 5.4 | 76 | male | 3 | 61 | 4.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.2 | false | MSS | 2026-03-15T05:35:59.846533+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_716585 | REC_0011925 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 10.3 | 53 | male | 0 | 11 | 6.5 | 3 | alectinib 600 mg BID | 4 | false | MSS | 2026-03-15T05:35:59.846770+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_217424 | REC_0011926 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 8.8 | 70 | female | 2 | 9 | 6.7 | 1 | entrectinib 600 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:59.846998+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_837944 | REC_0011927 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 11.3 | 68 | male | 1 | 15 | 3.7 | 2 | osimertinib 80 mg daily | 4.8 | true | MSI-H | 2026-03-15T05:35:59.847234+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235168 | REC_0011928 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 7.2 | 74 | female | 2 | 24 | 6.3 | 2 | alectinib 600 mg BID | 11.7 | true | MSS | 2026-03-15T05:35:59.847464+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_662892 | REC_0011929 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 16.8 | 70 | male | 2 | 14 | 3.7 | 6 | pembrolizumab 200 mg q3w | 12 | false | MSS | 2026-03-15T05:35:59.847700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_499940 | REC_0011930 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 15.9 | 70 | male | 0 | 18 | 5.8 | 5 | entrectinib 600 mg daily | 18.7 | true | MSI-H | 2026-03-15T05:35:59.847934+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_373554 | REC_0011931 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 9.1 | 57 | male | 0 | 7 | 4.5 | 5 | alectinib 600 mg BID | 6.4 | false | MSS | 2026-03-15T05:35:59.848231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_715672 | REC_0011932 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 27 | 4.4 | 66 | male | 0 | 14 | 5.5 | 2 | pembrolizumab 200 mg q3w | 24.1 | true | MSS | 2026-03-15T05:35:59.848471+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_926811 | REC_0011933 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 9.1 | 65 | female | 1 | 14 | 5.2 | 6 | sotorasib 960 mg daily | 12.2 | false | MSS | 2026-03-15T05:35:59.848712+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322914 | REC_0011934 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 6.9 | 74 | female | 2 | 15 | 5.8 | 1 | entrectinib 600 mg daily | 14 | false | MSS | 2026-03-15T05:35:59.848943+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_521514 | REC_0011935 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 11.9 | 81 | female | 2 | 13 | 6.5 | 1 | sotorasib 960 mg daily | 25.3 | true | MSS | 2026-03-15T05:35:59.849226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132160 | REC_0011936 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 16.2 | 63 | female | 0 | 11 | 5.6 | 7 | entrectinib 600 mg daily | 14.1 | false | MSI-H | 2026-03-15T05:35:59.849465+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_651029 | REC_0011937 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 14.5 | 52 | female | 0 | 17 | 6.8 | 1 | osimertinib 80 mg daily | 13.2 | true | MSS | 2026-03-15T05:35:59.849703+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638503 | REC_0011938 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 5.6 | 57 | male | 1 | 10 | 5.1 | 1 | sotorasib 960 mg daily | 17.2 | false | MSS | 2026-03-15T05:35:59.849935+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_341889 | REC_0011939 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 5.6 | 82 | female | 2 | 4 | 6 | 4 | pembrolizumab 200 mg q3w | 13 | true | MSS | 2026-03-15T05:35:59.850165+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_778742 | REC_0011940 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 29 | 10.4 | 73 | male | 1 | 16 | 6.9 | 0 | osimertinib 80 mg daily | 41.7 | false | MSS | 2026-03-15T05:35:59.850399+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445268 | REC_0011941 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 5.7 | 75 | female | 1 | 56 | 5.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 27.6 | false | MSS | 2026-03-15T05:35:59.850627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_780214 | REC_0011942 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 4.8 | 61 | female | 0 | 20 | 3.6 | 6 | osimertinib 80 mg daily | 11 | false | MSS | 2026-03-15T05:35:59.850867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_401570 | REC_0011943 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 12.5 | 64 | female | 0 | 7 | 5.9 | 1 | osimertinib 80 mg daily | 23.2 | false | MSI-H | 2026-03-15T05:35:59.851105+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_662889 | REC_0011944 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 14.9 | 67 | male | 1 | 13 | 5 | 7 | osimertinib 80 mg daily | 12.9 | false | MSI-H | 2026-03-15T05:35:59.851340+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_770012 | REC_0011945 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 7.3 | 78 | female | 2 | 19 | 5.5 | 0 | carboplatin + paclitaxel + pembrolizumab | 20.7 | true | MSS | 2026-03-15T05:35:59.851570+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849506 | REC_0011946 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 7.7 | 63 | female | 1 | 14 | 5.5 | 5 | osimertinib 80 mg daily | 18.4 | true | MSS | 2026-03-15T05:35:59.851802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_336284 | REC_0011947 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 11.2 | 62 | male | 1 | 11 | 6.3 | 2 | entrectinib 600 mg daily | 22.1 | false | MSI-H | 2026-03-15T05:35:59.852037+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_250864 | REC_0011948 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 31 | 13.5 | 60 | female | 0 | 23 | 7.3 | 1 | sotorasib 960 mg daily | 25 | false | MSI-H | 2026-03-15T05:35:59.852383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_789413 | REC_0011949 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 8.3 | 62 | female | 0 | 13 | 7.2 | 7 | sotorasib 960 mg daily | 13.6 | false | MSS | 2026-03-15T05:35:59.852624+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_715092 | REC_0011950 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 13.7 | 70 | female | 3 | 17 | 8.2 | 5 | alectinib 600 mg BID | 9.1 | false | MSI-H | 2026-03-15T05:35:59.852864+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_984722 | REC_0011951 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 3 | 58 | female | 0 | 12 | 6.1 | 7 | pembrolizumab 200 mg q3w | 21.4 | false | MSS | 2026-03-15T05:35:59.853098+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_498963 | REC_0011952 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 10.2 | 74 | female | 2 | 12 | 8 | 5 | sotorasib 960 mg daily | 6 | false | MSI-H | 2026-03-15T05:35:59.853330+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_962755 | REC_0011953 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 9.6 | 71 | female | 2 | 20 | 5.5 | 5 | pembrolizumab 200 mg q3w | 11 | true | MSS | 2026-03-15T05:35:59.853561+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_375354 | REC_0011954 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 16 | 7.9 | 73 | female | 2 | 71 | 5.5 | 3 | carboplatin + paclitaxel + pembrolizumab | 10.7 | false | MSS | 2026-03-15T05:35:59.853790+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_581116 | REC_0011955 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 18.9 | 73 | female | 2 | 7 | 7 | 4 | osimertinib 80 mg daily | 11 | true | MSI-H | 2026-03-15T05:35:59.854023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189069 | REC_0011956 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 7.4 | 71 | female | 2 | 13 | 7 | 4 | osimertinib 80 mg daily | 11.1 | true | MSS | 2026-03-15T05:35:59.854247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_229700 | REC_0011957 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 7 | 77 | female | 1 | 15 | 4.9 | 2 | pembrolizumab 200 mg q3w | 10.3 | true | MSS | 2026-03-15T05:35:59.854473+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_704104 | REC_0011958 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 15.7 | 68 | male | 0 | 3 | 5.6 | 7 | entrectinib 600 mg daily | 9.6 | false | MSS | 2026-03-15T05:35:59.854754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_414200 | REC_0011959 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 10.5 | 69 | female | 0 | 14 | 5.6 | 1 | alectinib 600 mg BID | 12.7 | true | MSI-H | 2026-03-15T05:35:59.854987+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915458 | REC_0011960 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 14.3 | 74 | female | 2 | 12 | 6.3 | 1 | osimertinib 80 mg daily | 9.6 | true | MSI-H | 2026-03-15T05:35:59.855217+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_708217 | REC_0011961 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 15 | 8.6 | 79 | female | 2 | 10 | 4.8 | 7 | sotorasib 960 mg daily | 7.1 | true | MSS | 2026-03-15T05:35:59.855494+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309283 | REC_0011962 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 13.1 | 62 | male | 1 | 26 | 6.4 | 4 | osimertinib 80 mg daily | 7.4 | false | MSI-H | 2026-03-15T05:35:59.855730+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_974095 | REC_0011963 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 14.3 | 79 | female | 1 | 20 | 4 | 7 | osimertinib 80 mg daily | 16.8 | false | MSS | 2026-03-15T05:35:59.855963+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116647 | REC_0011964 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 2.9 | 57 | male | 0 | 38 | 6.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 9 | true | MSS | 2026-03-15T05:35:59.856229+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_990894 | REC_0011965 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 8 | 53 | male | 0 | 14 | 3.9 | 8 | alectinib 600 mg BID | 8.1 | false | MSS | 2026-03-15T05:35:59.856523+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_924900 | REC_0011966 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 12.9 | 64 | male | 1 | 12 | 5 | 6 | alectinib 600 mg BID | 6.5 | false | MSI-H | 2026-03-15T05:35:59.857118+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626541 | REC_0011967 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 12.6 | 69 | female | 1 | 15 | 6.6 | 1 | sotorasib 960 mg daily | 17.4 | false | MSS | 2026-03-15T05:35:59.857445+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_672845 | REC_0011968 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 4 | 69 | male | 1 | 51 | 5.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 5.5 | false | MSS | 2026-03-15T05:35:59.857680+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_226102 | REC_0011969 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 10.2 | 70 | female | 1 | 9 | 7 | 6 | sotorasib 960 mg daily | 7.4 | false | MSS | 2026-03-15T05:35:59.857910+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_386618 | REC_0011970 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 11.7 | 70 | female | 1 | 17 | 5.5 | 5 | pembrolizumab 200 mg q3w | 17.6 | true | MSI-H | 2026-03-15T05:35:59.858141+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_604533 | REC_0011971 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 17 | 69 | male | 1 | 23 | 6.1 | 5 | entrectinib 600 mg daily | 13 | true | MSS | 2026-03-15T05:35:59.858376+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865233 | REC_0011972 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 7.9 | 74 | male | 2 | 3 | 5.3 | 0 | entrectinib 600 mg daily | 11.3 | false | MSS | 2026-03-15T05:35:59.858608+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_245855 | REC_0011973 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 13 | 77 | female | 1 | 18 | 6.2 | 5 | alectinib 600 mg BID | 20.6 | true | MSS | 2026-03-15T05:35:59.858839+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_237432 | REC_0011974 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 8.7 | 59 | male | 1 | 20 | 5.9 | 4 | entrectinib 600 mg daily | 18.3 | true | MSS | 2026-03-15T05:35:59.859127+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507728 | REC_0011975 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 11.2 | 61 | female | 0 | 13 | 5.3 | 6 | sotorasib 960 mg daily | 9.7 | false | MSI-H | 2026-03-15T05:35:59.859367+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_522851 | REC_0011976 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 34 | 5.2 | 63 | male | 1 | 11 | 4.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 11.8 | true | MSS | 2026-03-15T05:35:59.859598+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535170 | REC_0011977 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 14.7 | 69 | female | 0 | 24 | 3.9 | 3 | alectinib 600 mg BID | 14.2 | false | MSS | 2026-03-15T05:35:59.859830+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_190514 | REC_0011978 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.3 | 72 | female | 0 | 40 | 5.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.7 | true | MSS | 2026-03-15T05:35:59.860057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_477236 | REC_0011979 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 8.1 | 71 | male | 3 | 14 | 6.3 | 2 | alectinib 600 mg BID | 27.8 | true | MSS | 2026-03-15T05:35:59.860327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_678006 | REC_0011980 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 4.2 | 67 | female | 0 | 58 | 5.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 25.2 | false | MSS | 2026-03-15T05:35:59.860558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_367250 | REC_0011981 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 1.9 | 56 | female | 0 | 34 | 7.2 | 9 | carboplatin + paclitaxel + pembrolizumab | 16.5 | true | MSS | 2026-03-15T05:35:59.860794+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_554829 | REC_0011982 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 14.8 | 66 | female | 0 | 16 | 4 | 4 | entrectinib 600 mg daily | 12.5 | true | MSS | 2026-03-15T05:35:59.861026+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_737594 | REC_0011983 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 18 | 8.2 | 61 | male | 0 | 32 | 7.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 18.2 | false | MSS | 2026-03-15T05:35:59.861257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_439835 | REC_0011984 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 15.3 | 77 | female | 2 | 18 | 6.4 | 3 | osimertinib 80 mg daily | 11.4 | true | MSS | 2026-03-15T05:35:59.861488+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_561084 | REC_0011985 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 5.8 | 72 | female | 0 | 31 | 5.3 | 6 | pembrolizumab 200 mg q3w | 9.9 | true | MSS | 2026-03-15T05:35:59.861715+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593064 | REC_0011986 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 7.7 | 71 | female | 1 | 19 | 7.8 | 2 | osimertinib 80 mg daily | 22.1 | true | MSS | 2026-03-15T05:35:59.861942+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_236365 | REC_0011987 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 32 | 10.8 | 68 | female | 0 | 9 | 6.6 | 2 | osimertinib 80 mg daily | 15.8 | false | MSS | 2026-03-15T05:35:59.862226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622902 | REC_0011988 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 5.9 | 55 | female | 1 | 43 | 6 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.5 | false | MSS | 2026-03-15T05:35:59.862460+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_698468 | REC_0011989 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 7.5 | 62 | male | 0 | 51 | 6.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 17.2 | false | MSS | 2026-03-15T05:35:59.862692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_122351 | REC_0011990 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 6 | 64 | male | 1 | 53 | 6.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.5 | true | MSS | 2026-03-15T05:35:59.862924+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697757 | REC_0011991 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 12.5 | 65 | male | 0 | 7 | 5.6 | 8 | osimertinib 80 mg daily | 7.4 | false | MSS | 2026-03-15T05:35:59.863162+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_279641 | REC_0011992 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 8.1 | 53 | male | 0 | 13 | 7.8 | 1 | osimertinib 80 mg daily | 29.6 | false | MSS | 2026-03-15T05:35:59.863395+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_203565 | REC_0011993 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 9.9 | 72 | female | 2 | 15 | 4.8 | 5 | sotorasib 960 mg daily | 6.6 | false | MSS | 2026-03-15T05:35:59.863622+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532794 | REC_0011994 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 8.6 | 70 | female | 2 | 28 | 4.2 | 8 | carboplatin + paclitaxel + pembrolizumab | 9.7 | true | MSS | 2026-03-15T05:35:59.863852+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457477 | REC_0011995 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 12.7 | 63 | female | 1 | 17 | 5.2 | 5 | alectinib 600 mg BID | 7.3 | false | MSI-H | 2026-03-15T05:35:59.864179+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_357010 | REC_0011996 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 15.8 | 62 | male | 1 | 21 | 6.2 | 7 | alectinib 600 mg BID | 11.2 | false | MSI-H | 2026-03-15T05:35:59.864437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673286 | REC_0011997 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 13.4 | 73 | female | 1 | 8 | 5.6 | 2 | osimertinib 80 mg daily | 21.9 | false | MSI-H | 2026-03-15T05:35:59.864674+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_818642 | REC_0011998 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 8.3 | 64 | female | 0 | 5 | 6.1 | 7 | alectinib 600 mg BID | 14.9 | false | MSS | 2026-03-15T05:35:59.864906+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_629562 | REC_0011999 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 15.6 | 62 | female | 0 | 10 | 5.8 | 6 | alectinib 600 mg BID | 4 | false | MSI-H | 2026-03-15T05:35:59.865143+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_660044 | REC_0012000 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 11.8 | 64 | male | 1 | 21 | 3.5 | 1 | sotorasib 960 mg daily | 25.4 | true | MSS | 2026-03-15T05:35:59.865427+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.